Gut Microbiota Dysbiosis and Metabolite Imbalance Mediate Diabetic Kidney Disease Inflammation: Mechanisms and Intervention Strategies Targeting Gut-Kidney Axis and NF-κB/NLRP3 Pathways - PubMed
4 hours ago
- #gut-kidney axis
- #inflammation
- #diabetic kidney disease
- Gut microbiota dysbiosis and metabolite imbalance play a key role in diabetic kidney disease (DKD) inflammation.
- DKD is characterized by reduced SCFA-producing bacteria and increased pathogenic Proteobacteria, leading to harmful metabolite accumulation.
- The imbalance impairs the intestinal barrier, promotes endotoxin translocation, and activates NF-κB and NLRP3 inflammasome pathways.
- Interventions like traditional Chinese medicine (TCM), SGLT2 inhibitors, and probiotics/prebiotics target these pathways to reduce inflammation.
- TCM (e.g., Astragalus membranaceus, Xiaoyaosan) reshapes microbiota, strengthens the intestinal barrier, and inhibits NF-κB/NLRP3.
- Clinical benefits include lower UACR, improved eGFR, and reduced pro-inflammatory cytokines (IL-1β, TNF-α).